

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-41. (Canceled)

42. (Currently Amended) A nucleic acid-lipid particle for introducing a nucleic acid into a cell, said particle comprising a cationic lipid, a non-cationic lipid, a conjugated lipid that inhibits aggregations of particles, and a nucleic acid, wherein said nucleic acid is encapsulated in the lipid of said particle and is resistant in aqueous solution to degradation with a nuclease, ~~and~~ wherein said particle has a charge ratio of cationic lipid to anionic nucleic acid of 1:1 to 8:1, and wherein:

said cationic lipid is a member selected from the group consisting of N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), and N,N-dimethyl-2,3-dioleoyloxy)propylamine (DODMA), and a mixture of two or more of the above;

said non-cationic lipid is selected from the group consisting of DOPE, POPC, and EPC; and

said conjugated lipid is a PEG-lipid.

43. (Canceled)

44. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said particle is substantially non-toxic.

45. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said particle has a median diameter of less than about 150 nm.

46.-49. (Canceled)

50. (Currently Amended) The nucleic acid-lipid particle of claim ~~49~~42, wherein said PEG-lipid comprises from 1% to about 15% of the lipid present in said particle.

51. (Currently Amended) The nucleic acid-lipid particle of claim ~~49~~42, wherein said PEG-lipid is PEG-ceramide.

52. (Previously Presented) The nucleic acid-lipid particle of claim 51, wherein the ceramide of said PEG-ceramide comprises a fatty acid group having 8 carbon atoms.

53. (Previously Presented) The nucleic acid-lipid particle of claim 51, wherein the ceramide of said PEG-ceramide comprises a fatty acid group having 14 carbon atoms.

54. (Previously Presented) The nucleic acid-lipid particle of claim 51, wherein the ceramide of said PEG-ceramide comprises a fatty acid group having 20 carbon atoms.

55. (Currently Amended) The nucleic acid-lipid particle of claim ~~49~~42, wherein said PEG-lipid is PEG-phosphatidylethanolamine.

56. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein the nucleic acid:lipid ratio within said particle is at least 5 mg nucleic acid per mmol lipid.

57. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein the nucleic acid:lipid ratio within said particle is at least 20 mg nucleic acid per mmol lipid.

58. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein the nucleic acid:lipid ratio within said particle is at least 40 mg nucleic per mmol lipid.

59. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is DNA.

60. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is a plasmid.

61. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is an antisense oligonucleotide.

62. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is a ribozyme.

63. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said cationic lipid comprises 50% or less of the lipid present in said particle.

64. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said cationic lipid comprises from an amount greater than 0% to about 20% of the lipid present in said particle.

65. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein the nucleic acid component of said particle is substantially not degraded after exposure of said particle to a nuclease at 37°C for 20 minutes.

66. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein the nucleic acid component of said particle is substantially not degraded after incubation of said particle in serum at 37°C for 30 minutes.

67. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein more than 10% of a plurality of such particles are present in plasma one hour after intravenous administration.

68. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein transformation of cells by said particle at a site distal to the site of administration is detectable for at least four days after intravenous injection.

69.-75. (Canceled)

76. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is an oligonucleotide.

77. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is RNA.

78. (Canceled)

79. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said nucleic acid is a DNA-RNA hybrid.

80. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said particle has a charge ratio of cationic lipid to anionic nucleic acid of 2:1 to 8:1.

81. (Previously Presented) The nucleic acid-lipid particle of claim 42, wherein said particle has a charge ratio of cationic lipid to anionic nucleic acid of 2:1 to 6:1.

82. (Canceled)

83. (Currently Amended) The nucleic acid-lipid particle of claim ~~82~~42, wherein said nucleic acid is a double-stranded RNA.